propylene glycol has been researched along with Dry Eye in 14 studies
Propylene Glycol: A clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations.
propane-1,2-diol : The simplest member of the class of propane-1,2-diols, consisting of propane in which a hydrogen at position 1 and a hydrogen at position 2 are substituted by hydroxy groups. A colourless, viscous, hygroscopic, low-melting (-59degreeC) and high-boiling (188degreeC) liquid with low toxicity, it is used as a solvent, emulsifying agent, and antifreeze.
Excerpt | Relevance | Reference |
---|---|---|
"Xanthan gum/chondroitin sulfate preservative free showed similar clinical efficacy, evaluated with OSDI score, TBUT and Schirmer test compared to polyethylene glycol/propylene glycol in the treatment of dry eye disease." | 9.22 | Efficacy of a fixed combination of 0.09 % xanthan gum/0.1 % chondroitin sulfate preservative free vs polyethylene glycol/propylene glycol in subjects with dry eye disease: a multicenter randomized controlled trial. ( Belalcazar-Rey, S; Ochoa-Tabares, JC; Oregón-Miranda, AA; Pérez-Balbuena, AL; Rodríguez-Carrizalez, AD; Saucedo-Rodríguez, LR; Suárez-Sánchez, RG; Urzúa-Salinas, C; Velasco-Ramos, R, 2016) |
"01%) loaded propylene glycol (PG) modified nano-vesicles (Proglycosomes Nano-vesicles, PNVs) for the treatment of experimental dry eye syndrome (DES) in rabbits." | 8.12 | Topical Tacrolimus Progylcosomes Nano-Vesicles As a Potential Therapy for Experimental Dry Eye Syndrome. ( Garg, V; Jain, GK; Kesharwani, P; Nirmal, J; Pandita, D; Warsi, MH, 2022) |
" The most frequently reported adverse event was eye irritation (HPG/PEG/PG, n=2; O/CMC, n=3)." | 6.84 | Safety and efficacy of a hydroxypropyl guar/polyethylene glycol/propylene glycol-based lubricant eye-drop in patients with dry eye. ( Baudouin, C; Labetoulle, M; Messmer, EM; Ogundele, A; Pisella, PJ, 2017) |
"To evaluate and compare the efficacy of a lipid-based lubricant eyedrop formulation (hydroxypropyl guar/propylene glycol/phospholipid [HPG/PG/PL]) with preservative-free saline for the treatment of dry eye." | 5.24 | Clinical evaluation of an oil-based lubricant eyedrop in dry eye patients with lipid deficiency. ( Baudouin, C; Böhringer, D; Galarreta, DJ; Guillon, M; Labetoulle, M; Maurino, V; Mrukwa-Kominek, E; Ogundele, A; Rossi, GC; Van der Meulen, IJ, 2017) |
"Xanthan gum/chondroitin sulfate preservative free showed similar clinical efficacy, evaluated with OSDI score, TBUT and Schirmer test compared to polyethylene glycol/propylene glycol in the treatment of dry eye disease." | 5.22 | Efficacy of a fixed combination of 0.09 % xanthan gum/0.1 % chondroitin sulfate preservative free vs polyethylene glycol/propylene glycol in subjects with dry eye disease: a multicenter randomized controlled trial. ( Belalcazar-Rey, S; Ochoa-Tabares, JC; Oregón-Miranda, AA; Pérez-Balbuena, AL; Rodríguez-Carrizalez, AD; Saucedo-Rodríguez, LR; Suárez-Sánchez, RG; Urzúa-Salinas, C; Velasco-Ramos, R, 2016) |
", Irvine, CA) and propylene glycol/polyethylene glycol 400 (PG-HPG) (Systane, Alcon, Fort Worth, TX) in providing relief of dry eye symptoms and signs." | 5.12 | Comparison of initial treatment response to two enhanced-viscosity artificial tears. ( Noecker, RJ, 2006) |
"To evaluate the efficacy of a new lubricant eye drop containing polyethylene glycol 400 and propylene glycol demulcents with hydroxypropyl-guar as a gelling agent (Test Product) to a system with carboxymethylcellulose (Control Product) for reducing dry eye signs and symptoms." | 5.11 | Clinical evaluation of an HP-guar gellable lubricant eye drop for the relief of dryness of the eye. ( Akers, F; Bloomenstein, M; Christensen, MT; Cohen, S; Hearn, C; Kaplan, D; Lesher, M; Meadows, D; Meuse, P; Pemberton, B; Rinehart, J; Stein, JM, 2004) |
"01%) loaded propylene glycol (PG) modified nano-vesicles (Proglycosomes Nano-vesicles, PNVs) for the treatment of experimental dry eye syndrome (DES) in rabbits." | 4.12 | Topical Tacrolimus Progylcosomes Nano-Vesicles As a Potential Therapy for Experimental Dry Eye Syndrome. ( Garg, V; Jain, GK; Kesharwani, P; Nirmal, J; Pandita, D; Warsi, MH, 2022) |
"Because of the added emphasis on ocular surface damage included in the Dry Eye Workshop's revised definition of dry eye, an evaluation of corneal staining reductions was conducted for propylene glycol/polyethylene glycol 400-based artificial tear drops (Systane Lubricant Eye Drops; Alcon Laboratories, Fort Worth, TX, USA)." | 3.74 | Corneal staining reductions observed after treatment with Systane Lubricant Eye Drops. ( Christensen, MT, 2008) |
" The most frequently reported adverse event was eye irritation (HPG/PEG/PG, n=2; O/CMC, n=3)." | 2.84 | Safety and efficacy of a hydroxypropyl guar/polyethylene glycol/propylene glycol-based lubricant eye-drop in patients with dry eye. ( Baudouin, C; Labetoulle, M; Messmer, EM; Ogundele, A; Pisella, PJ, 2017) |
"Twenty patients with moderate to severe dry eye were enrolled in a 28-day prospective, randomized, controlled study." | 2.74 | Protecting the ocular surface and improving the quality of life of dry eye patients: a study of the efficacy of an HP-guar containing ocular lubricant in a population of dry eye patients. ( Autori, S; Badino, F; Barabino, S; Rolando, M, 2009) |
"Ocular surface discomfort and dry eye disease are caused by a dysfunctional tear film." | 1.91 | Modulation of mucin secretion using combined polyethylene glycol-propylene glycol topical formulation in a hyperosmotic stress-based explant model. ( D'Souza, S; Gorimapalli, B; James, E; Khamar, P; Panigrahi, T, 2023) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (35.71) | 29.6817 |
2010's | 6 (42.86) | 24.3611 |
2020's | 3 (21.43) | 2.80 |
Authors | Studies |
---|---|
Garg, V | 1 |
Nirmal, J | 1 |
Warsi, MH | 1 |
Pandita, D | 1 |
Kesharwani, P | 1 |
Jain, GK | 1 |
Panigrahi, T | 1 |
James, E | 1 |
Khamar, P | 1 |
Gorimapalli, B | 1 |
D'Souza, S | 1 |
Garofalo, R | 1 |
Kunnen, C | 1 |
Rangarajan, R | 2 |
Manoj, V | 1 |
Ketelson, H | 1 |
Kraybill, B | 1 |
Ogundele, A | 3 |
Ketelson, HA | 1 |
Labetoulle, M | 2 |
Messmer, EM | 1 |
Pisella, PJ | 1 |
Baudouin, C | 2 |
Pérez-Balbuena, AL | 1 |
Ochoa-Tabares, JC | 1 |
Belalcazar-Rey, S | 1 |
Urzúa-Salinas, C | 1 |
Saucedo-Rodríguez, LR | 1 |
Velasco-Ramos, R | 1 |
Suárez-Sánchez, RG | 1 |
Rodríguez-Carrizalez, AD | 1 |
Oregón-Miranda, AA | 1 |
Galarreta, DJ | 1 |
Mrukwa-Kominek, E | 1 |
Böhringer, D | 1 |
Maurino, V | 1 |
Guillon, M | 1 |
Rossi, GC | 1 |
Van der Meulen, IJ | 1 |
Christensen, MT | 3 |
Rolando, M | 1 |
Autori, S | 1 |
Badino, F | 1 |
Barabino, S | 1 |
Springs, C | 1 |
Springs, CL | 1 |
Cohen, S | 1 |
Rinehart, J | 1 |
Akers, F | 1 |
Pemberton, B | 1 |
Bloomenstein, M | 1 |
Lesher, M | 1 |
Kaplan, D | 1 |
Meadows, D | 1 |
Meuse, P | 1 |
Hearn, C | 1 |
Stein, JM | 1 |
Noecker, RJ | 1 |
Ousler, GW | 1 |
Michaelson, C | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Clinical Evaluation of Systane® ULTRA Compared to OPTIVE® in Ocular Surface Staining[NCT01863368] | 105 participants (Actual) | Interventional | 2013-09-30 | Completed | |||
A Randomized, Double-blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of PRO-148 Versus Systane®, in Patients With Mild to Moderate Dry Eye[NCT01657253] | Phase 3 | 183 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
A Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye: A Randomized Controlled Trial[NCT00386646] | Phase 4 | 100 participants | Interventional | 2004-02-29 | Completed | ||
A Randomized, Masked Exploratory Trial Comparing the Effect of Two Different Over-the-Counter Artificial Tear Preparations on Tear Film Break-up Time[NCT00681265] | 16 participants (Actual) | Interventional | 2008-06-30 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The TOSS score is a composite score of corneal fluorescein staining, nasal conjunctival lissamine green staining, and temporal conjunctival lissamine green staining, each scored on a 0-5 Likert scale (0=absent, 5=severe). TOSS scores can range from 0 to 15. One eye (study eye) contributed to the analysis. (NCT01863368)
Timeframe: Baseline, Day 35
Intervention | units on a scale (Mean) |
---|---|
Systane Ultra | -2.2 |
Optive | -1.7 |
The IDEEL is a 10-item, patient-reported questionnaire used to measure treatment satisfaction. The subject answered 4 questions pertaining to treatment effectiveness scored on a 0-4 Likert-type scale, where 0=None of the time, 1=A little of the time, 2=Some of the time, 3=Most of the time, and 4=All of the time. The IDEEL score for treatment effectiveness was calculated based upon the mean value of the 4 questions multiplied by 25, for a resultant overall score of 0-100, where 0=Complete disability and 100=No disability. Both eyes contributed to the analysis. (NCT01863368)
Timeframe: Day 35
Intervention | units on a scale (Mean) |
---|---|
Systane Ultra | 62.2 |
Optive | 55.7 |
The IDEEL is a 10-item, patient-reported questionnaire used to measure treatment satisfaction. The subject answered 4 questions pertaining to treatment inconvenience scored on a 0-4 Likert-type scale, where 0=All of the time, 1=Most of the time, 2=Some of the time, 3=A little of the time, and 4=None of the time. The IDEEL score for treatment inconvenience was calculated based upon the mean value of the 4 questions multiplied by 25, for a resultant overall score of 0-100, where 0=Complete disability and 100=No disability. Both eyes contributed to the analysis. (NCT01863368)
Timeframe: Day 35
Intervention | units on a scale (Mean) |
---|---|
Systane Ultra | 69.5 |
Optive | 67.1 |
The OSDI is a 12-item, quality of life questionnaire that evaluates symptoms based on 3 modules (type of discomfort, environmental triggers, and tasking) on a 0-4 Likert scale (0=None of the time, 4=All of the time). A resultant overall 0-100 score was calculated, where 0=No disability and 100=Complete disability. Both eyes contributed to the analysis. (NCT01863368)
Timeframe: Day 35
Intervention | units on a scale (Mean) |
---|---|
Systane Ultra | 31.0 |
Optive | 35.4 |
Ocular Surface Disease Index (OSDI©) questionnaire , consists of 12 questions divided in 3 groups, Each question has a value that can go from 0 to 4 points according to the severity of the case: 0.None of the time, 1. Some of the time, 2.Half of the time, 3.most of the time and 4 all of the time. The points of all the questions will be used in the following formula for converted to a score of 0-100 : (sum of scores) x 25 / (# of questions answered), where 0 represents normality or non-symptomatology and 100 the most severe case. Will be used to measure the symptoms of dry eye disease by obtaining baseline data and comparing them against the last visit. (NCT01657253)
Timeframe: Day 60
Intervention | points (Mean) | |
---|---|---|
baseline values | final values | |
PRO-148 | 19.3 | 7.3 |
Systane® | 19.3 | 7.9 |
"Change from Baseline in Schirmer test after 60 days of treatment~Schirmer test~It is the technique most used to measure aqueous and at the same time the simplest tear secretion. It is carried out as follows: Without applying anesthesia, the patient is placed somewhere without much illumination, without applying anesthesia, a strip of filter paper of approximately 30 mm is placed, of which, 5 mm must go in the joint Of the middle and outer third of the lower eyelid. The patient is instructed to look forward and to blink normally. After 5 minutes the strips are removed and the wetting is recorded in millimeters. A test less than or equal to 6 mm is diagnostic of aqueous deficiency.The mean of the revisions by group will be compared at the baseline and final visit." (NCT01657253)
Timeframe: Day 60
Intervention | mm/min (Mean) | |
---|---|---|
baseline values | final values | |
PRO-148 | 6.4 | 11.0 |
Systane® | 6.5 | 10.5 |
Change from Baseline in Tear film break up time after 60 days of treatment Tear film breakup time is the elapsed time from blinking to the first occurrence of a dry area in the cornea, visualized with the help of fluorescein staining. Measurement of tear film breakup time will be performed as follows: Fluorescein is instilled in the eye, the patient is asked to blink three times to distribute the dye and then set the eye to the front and do not blink while the examiner observes the cornea with cobalt blue light, looking for an area of tear film rupture, which is manifested by the appearance of a black island within the fluorescein green film. Normally film breakup time is 10 seconds or more and the minimum register may be 1 second, Under 10 seconds is considered abnormal. (NCT01657253)
Timeframe: Day 60
Intervention | seconds (Mean) | |
---|---|---|
baseline values | final values | |
PRO-148 | 5.5 | 7.4 |
Systane® | 5.2 | 7.4 |
Standard clinical assessment methodology for assessing tear stability. (NCT00681265)
Timeframe: 120 minutes after eye drops instillation
Intervention | seconds (Mean) |
---|---|
New Formulation of Glycerin 1% Eye Drop | 11.13 |
Propylene Glycol and PEG 400 Eye Drop | 6.21 |
State-of-the-art methodology to assess tear stability. (NCT00681265)
Timeframe: 15 minutes after eye drop instillation
Intervention | seconds (Mean) |
---|---|
New Formulation of Glycerin 1% Eye Drop | 14.67 |
Propylene Glycol and PEG 400 Eye Drop | 7.4 |
3 reviews available for propylene glycol and Dry Eye
Article | Year |
---|---|
Relieving the symptoms of dry eye disease: update on lubricating eye drops containing hydroxypropyl-guar.
Topics: Cyamopsis; Dry Eye Syndromes; Humans; Lubricant Eye Drops; Ophthalmic Solutions; Propylene Glycol; T | 2021 |
Novel ocular lubricant containing an intelligent delivery system: details of its mechanism of action.
Topics: Drug Combinations; Drug Delivery Systems; Dry Eye Syndromes; Humans; Ophthalmic Solutions; Polyethyl | 2010 |
Novel hydroxypropyl-guar gellable lubricant eye drops for treatment of dry eye.
Topics: Dry Eye Syndromes; Humans; Hydrogen-Ion Concentration; Ophthalmic Solutions; Polyethylene Glycols; P | 2010 |
7 trials available for propylene glycol and Dry Eye
Article | Year |
---|---|
Safety and efficacy of a hydroxypropyl guar/polyethylene glycol/propylene glycol-based lubricant eye-drop in patients with dry eye.
Topics: Dry Eye Syndromes; Female; France; Germany; Humans; Lubricants; Male; Middle Aged; Ophthalmic Soluti | 2017 |
Efficacy of a fixed combination of 0.09 % xanthan gum/0.1 % chondroitin sulfate preservative free vs polyethylene glycol/propylene glycol in subjects with dry eye disease: a multicenter randomized controlled trial.
Topics: Adult; Aged; Chondroitin Sulfates; Double-Blind Method; Dry Eye Syndromes; Eye Pain; Female; Humans; | 2016 |
Clinical evaluation of an oil-based lubricant eyedrop in dry eye patients with lipid deficiency.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dry Eye Syndromes; Emulsions; Female; Humans; Lipids; Lu | 2017 |
Protecting the ocular surface and improving the quality of life of dry eye patients: a study of the efficacy of an HP-guar containing ocular lubricant in a population of dry eye patients.
Topics: Administration, Topical; Adult; Aged; Drug Combinations; Dry Eye Syndromes; Humans; Middle Aged; Oph | 2009 |
Clinical evaluation of an HP-guar gellable lubricant eye drop for the relief of dryness of the eye.
Topics: Carboxymethylcellulose Sodium; Conjunctiva; Cornea; Double-Blind Method; Drug Evaluation; Drug Thera | 2004 |
Comparison of initial treatment response to two enhanced-viscosity artificial tears.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carboxymethylcellulose Sodium; Conjunctiva; Cornea; Drug | 2006 |
An evaluation of tear film breakup time extension and ocular protection index scores among three marketed lubricant eye drops.
Topics: Adult; Aged; Aged, 80 and over; Blinking; Carboxymethylcellulose Sodium; Cross-Over Studies; Double- | 2007 |
4 other studies available for propylene glycol and Dry Eye
Article | Year |
---|---|
Topical Tacrolimus Progylcosomes Nano-Vesicles As a Potential Therapy for Experimental Dry Eye Syndrome.
Topics: Animals; Dry Eye Syndromes; Inflammation; Propylene Glycol; Rabbits; Tacrolimus; Tears | 2022 |
Modulation of mucin secretion using combined polyethylene glycol-propylene glycol topical formulation in a hyperosmotic stress-based explant model.
Topics: CA-125 Antigen; Dry Eye Syndromes; Humans; Mucins; Polyethylene Glycols; Propylene Glycol; Tears | 2023 |
Effects of a Hyaluronic Acid/Hydroxypropyl Guar Artificial Tear Solution on Protection, Recovery, and Lubricity in Models of Corneal Epithelium.
Topics: Cell Survival; Cornea; Cross-Over Studies; Drug Evaluation, Preclinical; Dry Eye Syndromes; Epitheli | 2015 |
Corneal staining reductions observed after treatment with Systane Lubricant Eye Drops.
Topics: Cornea; Diagnostic Techniques, Ophthalmological; Drug Combinations; Dry Eye Syndromes; Humans; Ophth | 2008 |